Literature DB >> 19228815

Endogenous suppression of mast cell development and survival by IL-4 and IL-10.

Kelly Speiran1, Daniel P Bailey, Josephine Fernando, Matthew Macey, Brian Barnstein, Motunrayo Kolawole, Dana Curley, Stephanie S Watowich, Peter J Murray, Carole Oskeritzian, John J Ryan.   

Abstract

Mast cell development is an important component of atopic and chronic inflammatory diseases such as asthma, multiple sclerosis, rheumatoid arthritis, and atherosclerosis. In this study, we found that IL-4 and IL-10 were produced constitutively in cultures of developing mast cells, correlating with mast cell purity. Deletion of either gene increased mast cell numbers and Fc epsilon RI expression during culture in IL-3 + stem cell factor (SCF). By adding exogenous IL-4 and IL-10 to bone marrow (BM) cultures containing IL-3 + SCF, we found that IL-4 + IL-10 suppressed mast cell development through mechanisms not used by either cytokine alone. IL-4 + IL-10 elicited a rapid cell death coincidental with reduced Kit receptor expression and signaling and enhanced mitochondrial damage and caspase activation. IL-4 or IL-10 costimulation, unlike either cytokine alone, altered mast cell ontogeny to yield predominantly macrophages in cultures that typically produce mast cells. This effect was observed consistently with unseparated BM cells, purified mouse BM stem cells, and erythrocyte-depleted human umbilical cord blood cells. These experiments demonstrated a major role for Stat6 and Stat3, but not the Stat3-induced transcriptional repressor Ets variant gene 3. Genetic background was also a critical factor, as BALB/c-derived BM cells were completely resistant to IL-10-mediated killing and expressed lower levels of IL-10R. Collectively, these results support the theory that IL-4 and IL-10 function as endogenous regulators of mast cell progenitor development, consistent with a role in immune homeostasis. Loss of this homeostasis, perhaps via genetic polymorphism, could contribute to the etiology of mast cell-associated disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19228815      PMCID: PMC2669408          DOI: 10.1189/jlb.0708448

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  87 in total

Review 1.  Atopy and asthma: genetic variants of IL-4 and IL-13 signalling.

Authors:  I Shirakawa; K A Deichmann; I Izuhara; I Mao; C N Adra; J M Hopkin
Journal:  Immunol Today       Date:  2000-02

2.  Childhood atopic asthma: positive association with a polymorphism of IL-4 receptor alpha gene but not with that of IL-4 promoter or Fc epsilon receptor I beta gene.

Authors:  A Takabayashi; K Ihara; Y Sasaki; Y Suzuki; S Nishima; K Izuhara; N Hamasaki; T Hara
Journal:  Exp Clin Immunogenet       Date:  2000

Review 3.  Immunologic basis of antigen-induced airway hyperresponsiveness.

Authors:  M Wills-Karp
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

4.  Inhibition of Kit expression by IL-4 and IL-10 in murine mast cells: role of STAT6 and phosphatidylinositol 3'-kinase.

Authors:  P Mirmonsef; C P Shelburne; C Fitzhugh Yeatman; H J Chong; J J Ryan
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

5.  Mast cells express IL-13R alpha 1: IL-13 promotes human lung mast cell proliferation and Fc epsilon RI expression.

Authors:  D Kaur; F Hollins; L Woodman; W Yang; P Monk; R May; P Bradding; C E Brightling
Journal:  Allergy       Date:  2006-09       Impact factor: 13.146

6.  Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL.

Authors:  Y A Mekori; A M Gilfillan; C Akin; K Hartmann; D D Metcalfe
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

7.  Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors.

Authors:  Atsushi Inagaki; Takashi Ishida; Toshihiko Ishii; Hirokazu Komatsu; Shinsuke Iida; Jianmin Ding; Kentaro Yonekura; Shogo Takeuchi; Yoshifusa Takatsuka; Atae Utsunomiya; Ryuzo Ueda
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

8.  Association between a C+33T polymorphism in the IL-4 promoter region and total serum IgE levels.

Authors:  I Suzuki; N Hizawa; E Yamaguchi; Y Kawakami
Journal:  Clin Exp Allergy       Date:  2000-12       Impact factor: 5.018

9.  Cutting edge: both activating and inhibitory Fc receptors expressed on mast cells regulate experimental allergic encephalomyelitis disease severity.

Authors:  Michaela Robbie-Ryan; Melinda B Tanzola; Virginia H Secor; Melissa A Brown
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

10.  Interleukin 10: a novel stimulatory factor for mast cells and their progenitors.

Authors:  L Thompson-Snipes; V Dhar; M W Bond; T R Mosmann; K W Moore; D M Rennick
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

View more
  21 in total

Review 1.  Mast cell homeostasis and the JAK-STAT pathway.

Authors:  J K Morales; Y T Falanga; A Depcrynski; J Fernando; J J Ryan
Journal:  Genes Immun       Date:  2010-06-10       Impact factor: 2.676

Review 2.  Mast cell plasticity and sphingosine-1-phosphate in immunity, inflammation and cancer.

Authors:  Carole A Oskeritzian
Journal:  Mol Immunol       Date:  2014-04-22       Impact factor: 4.407

3.  IL-33/ST2 axis promotes mast cell survival via BCLXL.

Authors:  Jun-Xia Wang; Shinjiro Kaieda; Sarah Ameri; Nadia Fishgal; Daniel Dwyer; Anthony Dellinger; Christopher L Kepley; Michael F Gurish; Peter A Nigrovic
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

Review 4.  T cell subsets and their signature cytokines in autoimmune and inflammatory diseases.

Authors:  Itay Raphael; Saisha Nalawade; Todd N Eagar; Thomas G Forsthuber
Journal:  Cytokine       Date:  2014-10-30       Impact factor: 3.861

5.  ADAM10 is required for SCF-induced mast cell migration.

Authors:  Travis W Faber; Nicholas A Pullen; Josephine F A Fernando; Elizabeth Motunrayo Kolawole; Jamie J A McLeod; Marcela Taruselli; Kathryn L Williams; Kevin O Rivera; Brian O Barnstein; Daniel H Conrad; John J Ryan
Journal:  Cell Immunol       Date:  2014-05-21       Impact factor: 4.868

Review 6.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

Review 7.  Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus.

Authors:  Hui Peng; Wei Wang; Mo Zhou; Rui Li; Hai-Feng Pan; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2013-05-25       Impact factor: 2.980

8.  Fluvastatin Suppresses Mast Cell and Basophil IgE Responses: Genotype-Dependent Effects.

Authors:  Elizabeth Motunrayo Kolawole; Jamie Josephine Avila McLeod; Victor Ndaw; Daniel Abebayehu; Brian O Barnstein; Travis Faber; Andrew J Spence; Marcela Taruselli; Anuya Paranjape; Tamara T Haque; Amina A Qayum; Qasim A Kazmi; Dayanjan S Wijesinghe; Jamie L Sturgill; Charles E Chalfant; David B Straus; Carole A Oskeritzian; John J Ryan
Journal:  J Immunol       Date:  2016-01-15       Impact factor: 5.422

9.  Helicobacter pylori: bacterial factors and the role of cytokines in the immune response.

Authors:  Tania Beatriz Romero-Adrián; Jorymar Leal-Montiel; Francisca Monsalve-Castillo; Edgardo Mengual-Moreno; Ernesto García McGregor; Lenis Perini; Ana Antúnez
Journal:  Curr Microbiol       Date:  2009-10-22       Impact factor: 2.188

10.  Genotype-dependent effects of TGF-β1 on mast cell function: targeting the Stat5 pathway.

Authors:  Josephine Fernando; Travis W Faber; Nicholas A Pullen; Yves T Falanga; Elizabeth Motunrayo Kolawole; Carole A Oskeritzian; Brian O Barnstein; Geethani Bandara; Geqiang Li; Lawrence B Schwartz; Sarah Spiegel; David B Straus; Daniel H Conrad; Kevin D Bunting; John J Ryan
Journal:  J Immunol       Date:  2013-09-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.